• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康相关生活质量在重度哮喘临床试验中的应用:一项系统评价

Use of Health Related Quality of Life in Clinical Trials for Severe Asthma: A Systematic Review.

作者信息

Lanario Joseph W, Burns Lorna

机构信息

Faculty of Health, University of Plymouth, Plymouth, UK.

出版信息

J Asthma Allergy. 2021 Aug 12;14:999-1010. doi: 10.2147/JAA.S320817. eCollection 2021.

DOI:10.2147/JAA.S320817
PMID:34408445
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8367083/
Abstract

BACKGROUND

Asthma Health Related Quality of Life (HRQoL) is an outcome important to patients with severe asthma and can provide clinicians with additional insight into the benefits of treatment. The aim of this systematic review is to examine the use and reporting of HRQoL questionnaires within randomised controlled trials (RCTs) of biologics, fevipiprant and bronchial thermoplasty.

METHODS

We followed the guidelines on the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) statement. Of the 2380 retrieved articles, 52 studies were identified for inclusion.

RESULTS

Sixty-three percent included an asthma HRQoL questionnaire. It was a secondary outcome in the majority of cases (73%). The proportion of studies including an asthma HRQoL questionnaire did not change significantly over a 20-year period. While the Asthma Quality of Life Questionnaire (AQLQ) was used in 45% of studies, 55% used a variety of 4 questionnaires. Most (70%) of the studies that included a HRQoL questionnaire did not report its subscale scores. Approximately half (52%) of studies that used HRQoL reported this in the abstract of the paper. A higher proportion of studies used an asthma control questionnaire compared to a HRQoL questionnaire (71% vs 63%).

CONCLUSION

In order to increase the use of asthma HRQoL questionnaires in RCTs of severe asthma treatments, the drivers and barriers to their use must first be understood. At present, the patients' perspective is underrepresented in RCTs of biologics, fevipiprant and bronchial thermoplasty for severe asthma.

摘要

背景

哮喘健康相关生活质量(HRQoL)是对重度哮喘患者很重要的一项结果,可为临床医生提供有关治疗益处的更多见解。本系统评价的目的是研究在生物制剂、法维吡兰特和支气管热成形术的随机对照试验(RCT)中HRQoL问卷的使用和报告情况。

方法

我们遵循系统评价和Meta分析的首选报告项目(PRISMA)声明的指南。在检索到的2380篇文章中,确定了52项研究纳入。

结果

63%的研究纳入了哮喘HRQoL问卷。在大多数情况下(73%),它是次要结果。在20年期间,纳入哮喘HRQoL问卷的研究比例没有显著变化。虽然45%的研究使用了哮喘生活质量问卷(AQLQ),但55%的研究使用了4种问卷中的多种。大多数(70%)纳入HRQoL问卷的研究未报告其分量表得分。使用HRQoL的研究中约有一半(52%)在论文摘要中报告了这一点。与HRQoL问卷相比,使用哮喘控制问卷的研究比例更高(71%对63%)。

结论

为了增加哮喘HRQoL问卷在重度哮喘治疗RCT中的使用,必须首先了解其使用的驱动因素和障碍。目前,在生物制剂、法维吡兰特和支气管热成形术治疗重度哮喘的RCT中,患者的观点代表性不足。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616c/8367083/f01dc1cdaca4/JAA-14-999-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616c/8367083/aa152560a43b/JAA-14-999-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616c/8367083/f01dc1cdaca4/JAA-14-999-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616c/8367083/aa152560a43b/JAA-14-999-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/616c/8367083/f01dc1cdaca4/JAA-14-999-g0002.jpg

相似文献

1
Use of Health Related Quality of Life in Clinical Trials for Severe Asthma: A Systematic Review.健康相关生活质量在重度哮喘临床试验中的应用:一项系统评价
J Asthma Allergy. 2021 Aug 12;14:999-1010. doi: 10.2147/JAA.S320817. eCollection 2021.
2
Bronchial thermoplasty for moderate or severe persistent asthma in adults.成人中重度持续性哮喘的支气管热成形术
Cochrane Database Syst Rev. 2014 Mar 3;2014(3):CD009910. doi: 10.1002/14651858.CD009910.pub2.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Comparing bronchial thermoplasty with biologicals for severe asthma: Systematic review and network meta-analysis.比较支气管热成形术与生物制剂治疗重度哮喘:系统评价与网状Meta分析。
Respir Med. 2023 Sep;216:107302. doi: 10.1016/j.rmed.2023.107302. Epub 2023 May 29.
5
Anti-IL5 therapies for asthma.用于哮喘的抗白细胞介素-5疗法。
Cochrane Database Syst Rev. 2017 Sep 21;9(9):CD010834. doi: 10.1002/14651858.CD010834.pub3.
6
Macrolides versus placebo for chronic asthma.大环内酯类药物与安慰剂治疗慢性哮喘的比较。
Cochrane Database Syst Rev. 2021 Nov 22;11(11):CD002997. doi: 10.1002/14651858.CD002997.pub5.
7
Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis.哮喘治疗对哮喘生活质量问卷和哮喘控制问卷评分影响的幅度:系统评价和网络荟萃分析。
J Allergy Clin Immunol. 2015 Oct;136(4):914-22. doi: 10.1016/j.jaci.2015.03.023. Epub 2015 May 1.
8
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
9
Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis.中重度慢性阻塞性肺疾病(COPD)患者的支持性自我管理:证据综合与经济分析
Health Technol Assess. 2015 May;19(36):1-516. doi: 10.3310/hta19360.
10
Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.奥马珠单抗治疗严重持续性过敏性哮喘:系统评价和经济评估。
Health Technol Assess. 2013 Nov;17(52):1-342. doi: 10.3310/hta17520.

引用本文的文献

1
BREATHEIN: Better understanding obstructive REspiratory Airway disease Treatment and HEalth: a nationwide INvestigative survey in Denmark-a study protocol.BREATHEIN:更好地理解阻塞性呼吸道疾病的治疗与健康:丹麦的一项全国性调查研究方案
BMJ Open. 2025 Aug 6;15(8):e099447. doi: 10.1136/bmjopen-2025-099447.
2
Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.儿童和青少年重症哮喘管理的新进展:聚焦度普利尤单抗和特泽鲁单抗。
Paediatr Drugs. 2023 Nov;25(6):677-693. doi: 10.1007/s40272-023-00589-4. Epub 2023 Sep 2.
3
Narrative review to capture patients' perceptions and opinions about non-response and response to biological therapy for severe asthma.

本文引用的文献

1
What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance.重度哮喘患者关心什么?探索附加哮喘药物及重要结局。
ERJ Open Res. 2021 Mar 29;7(1). doi: 10.1183/23120541.00497-2020. eCollection 2021 Jan.
2
Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials.法维帕兰特减少重度哮喘患者病情加重的有效性(LUSTER-1和LUSTER-2):两项3期随机对照试验
Lancet Respir Med. 2021 Jan;9(1):43-56. doi: 10.1016/S2213-2600(20)30412-4. Epub 2020 Sep 24.
3
A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
叙述性综述,以了解患者对严重哮喘的生物治疗无应答和应答的看法和意见。
Eur Respir J. 2023 Jan 19;61(1). doi: 10.1183/13993003.00837-2022. Print 2023 Jan.
一项评估 lebrikizumab 对未控制哮喘气道嗜酸性粒细胞炎症和重塑影响的随机、安慰剂对照试验(CLAVIER)。
Clin Exp Allergy. 2020 Dec;50(12):1342-1351. doi: 10.1111/cea.13731. Epub 2020 Oct 4.
4
Bronchial Thermoplasty Induced Airway Smooth Muscle Reduction and Clinical Response in Severe Asthma. The TASMA Randomized Trial.支气管热成形术诱导的气道平滑肌减少与重度哮喘的临床反应。TASMA 随机试验。
Am J Respir Crit Care Med. 2021 Jan 15;203(2):175-184. doi: 10.1164/rccm.201911-2298OC.
5
Single-Session Bronchial Thermoplasty Guided by Xe Magnetic Resonance Imaging. A Pilot Randomized Controlled Clinical Trial.单次支气管热成形术指导下的氙磁共振成像。一项先导随机对照临床试验。
Am J Respir Crit Care Med. 2020 Aug 15;202(4):524-534. doi: 10.1164/rccm.201905-1021OC.
6
Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA).在重度嗜酸性粒细胞性哮喘患者中使用贝那利珠单抗的起效时间、气流阻塞和肺容积变化以及与健康相关的生活质量改善:IIIb期随机对照试验(SOLANA)
J Asthma Allergy. 2020 Feb 17;13:115-126. doi: 10.2147/JAA.S240044. eCollection 2020.
7
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.固定剂量皮下注射瑞利珠单抗对重度未控制哮喘患者哮喘恶化的影响和对口服糖皮质激素依赖哮喘患者糖皮质激素节省作用的影响:两项 3 期、随机、双盲、安慰剂对照试验的结果。
Lancet Respir Med. 2020 May;8(5):461-474. doi: 10.1016/S2213-2600(19)30372-8. Epub 2020 Feb 14.
8
A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men.一项评估皮下特泽鲁单抗在健康日本男性中的安全性、耐受性、药代动力学和免疫原性的 1 期、随机、安慰剂对照研究。
Clin Pharmacol Drug Dev. 2020 Oct;9(7):833-840. doi: 10.1002/cpdd.775. Epub 2020 Jan 20.
9
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline.重度哮喘的管理:欧洲呼吸学会/美国胸科学会指南
Eur Respir J. 2020 Jan 2;55(1). doi: 10.1183/13993003.00588-2019. Print 2020 Jan.
10
Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.应用结构统计学分析鉴定出一种生物标志物,可预测重度、未控制哮喘的 III 期临床试验中特拉普利单抗的疗效增强。
BMC Pulm Med. 2019 Jul 17;19(1):129. doi: 10.1186/s12890-019-0889-4.